8-K: BIO-KEY Secures $1M High-Cost Debt, Pledges All Assets

BIO-KEY International, Inc. has secured a $1.13 million senior secured promissory note from Streeterville Capital, LLC, providing $1 million in net proceeds for working capital at a high effective cost and pledging substantially all company assets.

Summary

• BIO-KEY International, Inc. (BKYI) entered into a Note Purchase Agreement with Streeterville Capital, LLC on September 30, 2025.
• BKYI issued a $1,130,000 principal amount senior secured promissory note.
• The note includes an original issue discount (OID) of $125,000 and $5,000 for the lender's transaction costs, resulting in net proceeds of $1,000,000 to BKYI for general working capital.
• The note matures 18 months from the issuance date and accrues interest at 9% per annum, compounded monthly.
• All payments are subject to a 7% exit fee on the principal amount repaid.
• The note is secured by a first-position lien on substantially all of BKYI's assets and properties, including intellectual property (patents and trademarks listed in Schedule 1 of the IP Security Agreement), and is guaranteed by its subsidiary, PistolStar, Inc.
• Starting six months after issuance (March 30, 2026), the lender can redeem up to $135,000 of principal monthly, which BKYI must pay within three trading days plus the exit fee.
• If BKYI does not reduce the outstanding balance by at least $135,000 monthly after the redemption start date, it must pay the difference plus the exit fee, or the outstanding balance automatically increases by 1%.
• Mandatory prepayments are required, equal to the lesser of 40% of proceeds from any future fundraising/financing (including warrant exercises) or the full outstanding balance, payable within five days of receiving such proceeds.
• Events of default can lead to an interest rate increase to 22% (or maximum legal rate) and acceleration of the note at a "Mandatory Default Amount," which includes a "Trigger Effect" increasing the outstanding balance by 5% to 15% per event, up to 25% aggregate.
• Covenants include timely SEC filings, maintaining Nasdaq listing, and restrictions on "Restricted Issuances" and new liens without lender consent.

Sentiment

Score: 2

Explanation: The financing terms are highly unfavorable, indicating significant financial distress or a very high-risk profile for BIO-KEY. The high effective cost of capital, extensive collateralization, strict repayment schedule, and punitive default clauses suggest a desperate need for capital and limited access to more conventional, less dilutive financing. This transaction places substantial burdens on the company's future financial flexibility and asset base.

Positives

• Secured $1,000,000 in immediate working capital to support ongoing operations.
• The company retains the ability to prepay the note in whole or in part without penalty, offering some flexibility if alternative financing becomes available.

Negatives

• The effective cost of capital is substantially high due to a $125,000 original issue discount, $5,000 in transaction fees, and a 7% exit fee on all principal repayments, in addition to the 9% annual interest rate.
• The note is secured by a first-position lien on substantially all of BIO-KEY's assets, including its valuable intellectual property, and is guaranteed by its subsidiary, PistolStar, Inc., indicating significant leverage and risk for the company.
• A strict monthly redemption obligation of $135,000 begins six months after issuance, with a 1% increase in the outstanding balance as a penalty for non-compliance, creating continuous liquidity pressure.
• A mandatory prepayment clause requires 40% of proceeds from any future fundraising or financing to be used for repayment, potentially hindering the company's ability to retain capital for growth or strategic investments.
• Punitive default terms include an interest rate increase to 22% and a "Trigger Effect" that can increase the outstanding balance by 5% to 15% per event, up to an aggregate of 25%.

Risks

• **Liquidity Risk**: The mandatory monthly redemption schedule and mandatory prepayment clause from future financings could severely strain liquidity and hinder the company's ability to retain capital for operations or growth.
• **Default Risk**: Failure to meet monthly redemption obligations, maintain Nasdaq listing, or timely file SEC reports could trigger an Event of Default, leading to accelerated repayment at a significantly higher cost (22% interest, Trigger Effect penalties).
• **Asset Encumbrance**: Substantially all of the company's assets, including its valuable intellectual property (patents and trademarks), are pledged as collateral, increasing the risk of asset forfeiture in case of default.
• **Dilution of Future Capital**: The mandatory prepayment from future fundraising could reduce the net proceeds available from subsequent capital raises, making it harder to secure growth capital.
• **Operational Restrictions**: Covenants against "Restricted Issuances" and new liens without lender consent could limit strategic financial decisions and operational flexibility.
• **Subsidiary Risk**: PistolStar, Inc. guaranteeing the note means its assets are also at risk, potentially impacting the consolidated entity's financial health.

Future Outlook

The proceeds from this financing are designated for general working capital, indicating a focus on sustaining current operations rather than specific growth initiatives. The stringent repayment terms and covenants suggest a cautious outlook on the company's near-term financial flexibility and ability to raise less dilutive capital.

Industry Context

This type of high-cost, heavily secured debt financing is often observed in companies facing liquidity challenges or with limited access to traditional capital markets. For a technology company in the biometrics and identity management space like BIO-KEY, securing financing with such terms, including pledging core intellectual property, could signal underlying financial distress or a perceived high risk by conventional lenders. It contrasts with growth-stage companies that typically secure equity or less restrictive debt to fund expansion.

Comparison to Industry Standards

• The 9% annual interest rate, coupled with a 7% exit fee and a 12.5% original issue discount (OID), results in a significantly higher effective cost of capital compared to typical senior secured debt for financially stable companies, which might see rates in the 4-8% range without such substantial fees or OID.
• The pledge of substantially all company assets, including intellectual property (patents and trademarks), is a common feature for distressed companies or those with limited tangible assets, but it is more restrictive than typical financing for established technology firms. For example, larger, more stable tech companies like Microsoft or Apple would secure debt against their strong balance sheets and cash flows, not their core IP in this manner.
• The mandatory monthly redemption schedule of $135,000 and the requirement to use 40% of future fundraising proceeds for prepayment are aggressive terms, often seen in 'death spiral' or highly predatory financing structures, designed to ensure rapid repayment or provide the lender with significant control and potential for further gains through default penalties. This is far more restrictive than standard corporate revolving credit facilities or term loans.
• The default interest rate of 22% and the 'Trigger Effect' penalties (5-15% increase in outstanding balance per event) are punitive and well above standard default provisions, which typically involve a smaller increase (e.g., 2-5%) over the base rate.

Stakeholder Impact

• **Shareholders**: Likely negative impact due to the high cost of debt, extensive asset collateralization, and potential for future equity dilution if the company struggles to meet debt obligations and needs to raise more capital under unfavorable terms. The mandatory prepayment clause also limits the company's ability to use future capital raises for growth, potentially impacting shareholder value.
• **Creditors**: The existing lender, Streeterville Capital, LLC, benefits from a first-position security interest on substantially all assets and a subsidiary guarantee, significantly improving its position relative to other unsecured creditors.
• **Employees**: The use of proceeds for 'general working capital' suggests a focus on maintaining current operations, which could provide short-term stability for employees, but the underlying financial distress indicated by the debt terms could pose long-term risks to job security if the company's financial health does not improve.
• **Customers/Suppliers**: Short-term stability from working capital could ensure continued operations and service delivery, but long-term financial instability could impact customer confidence and supplier relationships.

Next Steps

• BIO-KEY International, Inc. must make monthly payments to reduce the outstanding balance by at least $135,000 starting six months from the note's issuance date (March 30, 2026).
• The company must ensure timely filing of all reports with the SEC and maintain the listing of its common stock on the Nasdaq Stock Market.
• The company must adhere to covenants regarding 'Restricted Issuances' and granting new liens, requiring lender consent for certain financial activities.
• The company must repay the full principal amount of $1,130,000 plus accrued interest and exit fees by the maturity date, 18 months from issuance (March 30, 2027).

Key Dates

Recommendation

The terms of this debt financing are highly punitive and indicative of severe financial distress. The substantial original issue discount, high interest rate, significant exit fee, and aggressive monthly redemption schedule create an extremely high effective cost of capital. Pledging substantially all assets, including core intellectual property, and a subsidiary guarantee, leaves little room for error or future flexibility. The mandatory prepayment clause on future capital raises further constrains the company's ability to fund growth. These terms suggest that BIO-KEY International, Inc. is in a precarious financial position, making the stock a 'strong sell' due to the high risk of default, asset forfeiture, and significant shareholder value erosion.

Keywords

BIO-KEY International, BKYI, Streeterville Capital, Secured Promissory Note, Debt Financing, Working Capital, Intellectual Property Security, Patents, Trademarks, Corporate Debt, SEC Filing, 8-K, Biometrics, Financing Agreement, PistolStar